Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Caplin Point Laboratories Ltd Stock Analysis

Mid Cap
Evaluated by 2813 users | BSE: 524742 | NSE: CAPLIPOINT |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Caplin Point Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
 Jun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 31.14%36.87%50.31%54.15%42.45%52.7%47.75%33.88%24.11%21.98%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1071271732523184025406498631,0611,122
Y-o-Y Gr. Rt.-18.5%36.3%45.5%26.4%26.2%34.4%20.2%33.1%23%-
Adjusted EPS (Rs.) 1.522.093.75.678.4212.3718.5822.325.932.0234.18
Y-o-Y Gr. Rt.-37.5%77%53.2%48.5%46.9%50.2%20%16.1%23.6%-
Book Value per Share (Rs.) 3.955.227.6811.8421.6729.7347.6978.03114.21144.95154.41
Adjusted Net Profit 11.515.82842.963.693.5141169196242259
Net Op. Cash Flow (Rs. Cr.) 27.93259.849.956.567.666.583.444.7266-
Debt to Cash Flow from Ops 0.250.150.060.040.050.010.010.010.820.06-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Caplin Point Laboratories Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 29%27.2%25.3%23%
Adjusted EPS 40.3%30.6%19.9%23.6%
Book Value per Share 49.246.244.926.9
Share Price 69.3% 25.7% 28.6% 68.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Jun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 36.6341.153.3855.3343.1352.9947.7433.8424.7822.722.84
Operating Profit Margin (%) 15.0319.622.6824.7528.1331.1836.1835.7430.1331.0231.17
Net Profit Margin (%) 10.7212.4416.2217.0619.9923.25262622.723.6823.05
Debt to Equity 0.230.120.060.020.020000.040.01-
Working Capital Days 97956147716795133176193-
Cash Conversion Cycle -33-50-57-49-68-51-1933112115-
Loading price chart...
Entity Percentage Holding
Promoters 69.03%
Institutions 2.95%
Non-Institutions 28.02%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Past 10 year's financial track record analysis by Moneyworkds4me indicates that Caplin Point Laboratories Ltd is a average quality company.

Caplin Point Laboratories Ltd's earnings have grown by 30.6%, whereas share price has appreciated 25.7% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Caplin Point Laboratories Ltd share price has appreciated 69.3% annually (CAGR) over the past ten years.

Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Caplin Point Laboratories Ltd is an average long term investment. However, you need to ensure you buy at a right price to earn good returns.

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback